14:40:32 Europe / Stockholm

Prenumeration

2024-07-18 12:48:00

Redeye strengthens its positive view of Vertiseit following a solid Q2 report, with 21% ARR growth and a healthy EBITDA – CAPEX margin. Following strong free cash flow and the share issue, Vertiseit is now net cash positive and ready for further M&A – and the pipeline is encouraging.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/